Tokyo Tape
Sign in
← PHC Holdings

Quarterly report · Q2

6523.TEDINET S100S7VD
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥166.8bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥85.5bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥356.4bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥170.6bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥89.1bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥4.2bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥2.5bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥10.5bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥8.5bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax−¥3.0bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥557m2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥179m2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥3.4bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥9.7bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)−¥2.5bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥743m2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥3.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.2bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥8.3bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥2.4bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥733m2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥8.5bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥570.4bnat 2023-09-30Cons.Assets IFRS
Total assets¥561.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥596.3bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥423.4bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥422.7bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥147.0bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥138.8bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥149.3bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥136.1bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥147.4bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥138.0bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥148.3bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥61.4bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥60.9bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥73.7bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥95.2bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥22.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥21.4bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥5.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥2.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥17.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥8.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥23.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥40.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥20.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-19.552023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥5.912023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥-25.842022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥9.612022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥66.62022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-19.552023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥5.882023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥-25.842022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥9.522022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥65.982022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio25.8%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.6%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.9%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30¥1.1bn
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥1.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥4.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue2023-04-01 → 2023-09-30¥52.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue external2023-04-01 → 2023-09-30¥52.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentsegment profit2023-04-01 → 2023-09-30¥4.7bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2023-04-01 → 2023-09-30¥51.1bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2023-04-01 → 2023-09-30¥51.1bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2023-04-01 → 2023-09-30¥2.5bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue2023-04-01 → 2023-09-30¥61.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue external2023-04-01 → 2023-09-30¥61.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.7bn
—segment totalrevenue2023-04-01 → 2023-09-30¥165.7bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥165.7bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥8.9bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30¥1.1bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥9.4bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue2022-04-01 → 2022-09-30¥55.4bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue external2022-04-01 → 2022-09-30¥55.4bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.0bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2022-04-01 → 2022-09-30¥49.3bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2022-04-01 → 2022-09-30¥49.3bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.7bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue2022-04-01 → 2022-09-30¥64.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue external2022-04-01 → 2022-09-30¥64.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentsegment profit2022-04-01 → 2022-09-30¥5.3bn
—segment totalrevenue2022-04-01 → 2022-09-30¥169.5bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥169.5bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥20.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 914
ItemContextValueUnit
Operating profit loss IFRSPrior1YTDDuration10540000000JPY
Finance income IFRSPrior1YTDDuration134000000JPY
Finance costs IFRSPrior1YTDDuration7280000000JPY
Profit loss before tax IFRSPrior1YTDDuration3395000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember5172000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember5409000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember3855000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_ReportableSegmentsMember14436000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_ReconcilingItemsMember372000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration14809000000JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember139000000JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember－JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember4000000JPY
Impairment losses pl IFRSPrior1YTDDuration_ReportableSegmentsMember143000000JPY
Impairment losses pl IFRSPrior1YTDDuration_ReconcilingItemsMember114000000JPY
Impairment losses pl IFRSPrior1YTDDuration257000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember52802000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember61835000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember51057000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember165695000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember1123000000JPY
Revenue from external customers IFRSCurrentYTDDuration166819000000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember52802000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember61835000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember51057000000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember165695000000JPY
Revenue IFRSCurrentYTDDuration_ReconcilingItemsMember1123000000JPY
Revenue IFRSCurrentYTDDuration166819000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember4730000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember1680000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember2533000000JPY
Operating profit loss IFRSCurrentYTDDuration_ReportableSegmentsMember8944000000JPY
Operating profit loss IFRSCurrentYTDDuration_ReconcilingItemsMember-4761000000JPY
Operating profit loss IFRSCurrentYTDDuration4182000000JPY
Finance income IFRSCurrentYTDDuration463000000JPY
Finance costs IFRSCurrentYTDDuration7675000000JPY
Profit loss before tax IFRSCurrentYTDDuration-3030000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember3548000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000HealthcareSolutionsReportableSegmentMember5248000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember4253000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_ReportableSegmentsMember13050000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_ReconcilingItemsMember332000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration13383000000JPY
Impairment losses pl IFRSCurrentYTDDuration_jpcrp040300-q2r_E36976-000DiabetesManagementReportableSegmentMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass